Monday, April 27, 2020 1:55:06 PM
Not sure about the supercomputer but remember that the Supercomputer is testing a model of viral infectivity, and looking at drugs that could prevent the drug from being able to infect human cells. This would stop spread. Ifenprodil may impact viral spread (as I have eluded to before). Indeed, the first model of the super computer testing listed Algernon as a drug option. However, Algernon is specifically looking at Ifenprodil to decrease cytokine storm as you mention.
The most important thing to remember is that it;s an NMDA antagonist, and this will help dampen the glutamatergic hyper-excitability response and can prevent cell death. Probably has an impact on the microvascular leakage of the endothelium by decreasing the cytokines that increase the leakage.
The most important thing to remember is that it;s an NMDA antagonist, and this will help dampen the glutamatergic hyper-excitability response and can prevent cell death. Probably has an impact on the microvascular leakage of the endothelium by decreasing the cytokines that increase the leakage.
Invest in the science.
Recent AGNPF News
- Grey Matters Announces Private Placement • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation • GlobeNewswire Inc. • 04/15/2026 08:01:00 PM
- Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation • GlobeNewswire Inc. • 03/31/2026 11:09:55 PM
- Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers • GlobeNewswire Inc. • 03/25/2026 11:00:00 AM
- Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing • GlobeNewswire Inc. • 12/31/2025 09:01:00 PM
- Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche • GlobeNewswire Inc. • 12/23/2025 09:01:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 12/09/2025 05:01:20 PM
- Algernon Closes Second Tranche of Private Placement Financing • GlobeNewswire Inc. • 11/29/2025 12:51:39 AM
- Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement • GlobeNewswire Inc. • 11/17/2025 12:00:00 PM
- Algernon Closes First Tranche of its Recently Announced Private Placement Financing • GlobeNewswire Inc. • 11/15/2025 12:55:26 AM
- Algernon Health Announces Private Placement • GlobeNewswire Inc. • 11/06/2025 12:04:28 PM
- Algernon Pharmaceuticals Completes Name Change to Algernon Health • GlobeNewswire Inc. • 10/15/2025 11:00:00 AM
- Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection • GlobeNewswire Inc. • 09/25/2025 11:00:00 AM
- Algernon Announces Preferred Share Class Approved at Annual and Special Meeting • GlobeNewswire Inc. • 09/19/2025 08:39:57 PM
